In a letter Monday to Acting FDA Commissioner Lester Crawford, Grassley noted allegations that retaliatory actions may be taken against David Graham. An official in the FDA's Office of Drug Safety, Graham testified before a Congressional committee Nov. 18 that the agency is not doing enough to protect the public from dangerous medications.
Grassley asked Crawford to address allegations Graham may be terminated or transferred from his position against his wishes.
Graham testified the agency attempted to suppress his research showing the dangers of the arthritis drug Vioxx, which was recently pulled from the market. He warned that five other prescription medications should also be removed from the market or, at least, carry stronger use restrictions.